{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:06:21Z","timestamp":1788959181011,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s44313-026-00167-w","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:10:03Z","timestamp":1788955803000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CRS and ICANS: Early detection and personalized management"],"prefix":"10.1007","volume":"61","author":[{"given":"Jinchul","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"167_CR1","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348. https:\/\/doi.org\/10.1056\/NEJMoa1709866.","journal-title":"N Engl J Med"},{"key":"167_CR2","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1707447.","journal-title":"N Engl J Med"},{"key":"167_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342. https:\/\/doi.org\/10.1056\/NEJMoa1914347.","journal-title":"N Engl J Med"},{"key":"167_CR4","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384:705\u201316. https:\/\/doi.org\/10.1056\/NEJMoa2024850.","journal-title":"N Engl J Med"},{"key":"167_CR5","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387:2220\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2206913.","journal-title":"N Engl J Med"},{"key":"167_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa2203478.","journal-title":"N Engl J Med"},{"key":"167_CR7","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol. 2022;22:85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6.","journal-title":"Nat Rev Immunol"},{"key":"167_CR8","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25:625\u201338. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758.","journal-title":"Biol Blood Marrow Transplant"},{"key":"167_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jtct.2025.03.011","volume":"31","author":"R Shouval","year":"2025","unstructured":"Shouval R, Strouse C, Kim S, et al. Cytokine release syndrome and neurotoxicity following CD19 CAR-T in B-cell lymphoma. Transplant Cell Ther. 2025;31:419\u201333. https:\/\/doi.org\/10.1016\/j.jtct.2025.03.011.","journal-title":"Transplant Cell Ther"},{"key":"167_CR10","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"DM Cordas dos Santos","year":"2024","unstructured":"Cordas dos Santos DM, Tix T, Shouval R, et al. A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy. Nat Med. 2024;30:2667\u201378. https:\/\/doi.org\/10.1038\/s41591-024-03084-6.","journal-title":"Nat Med"},{"key":"167_CR11","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","volume":"5","author":"U Greenbaum","year":"2021","unstructured":"Greenbaum U, Strati P, Saliba RM, et al. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv. 2021;5:2799\u2013806. https:\/\/doi.org\/10.1182\/bloodadvances.2021004575.","journal-title":"Blood Adv"},{"key":"167_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-024-01579-w","volume":"17","author":"P Sesques","year":"2024","unstructured":"Sesques P, Kirkwood AA, Kwon M, et al. Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma. J Hematol Oncol. 2024;17:61. https:\/\/doi.org\/10.1186\/s13045-024-01579-w.","journal-title":"J Hematol Oncol"},{"key":"167_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0041-7.","journal-title":"Nat Med"},{"key":"167_CR14","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348. https:\/\/doi.org\/10.1038\/s41591-018-0036-4.","journal-title":"Nat Med"},{"key":"167_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s44313-025-00119-w","volume":"61","author":"ZG Chen","year":"2026","unstructured":"Chen ZG, Yang H, Yang C, et al. Macrophage polarization in hematologic cancers: mechanisms and therapeutic strategies. Blood Res. 2026;61:8. https:\/\/doi.org\/10.1007\/s44313-025-00119-w.","journal-title":"Blood Res"},{"key":"167_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188\u201395. https:\/\/doi.org\/10.1182\/blood-2014-05-552729.","journal-title":"Blood"},{"key":"167_CR17","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130:2295\u2013306. https:\/\/doi.org\/10.1182\/blood-2017-06-793141.","journal-title":"Blood"},{"key":"167_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","volume":"6","author":"DT Teachey","year":"2016","unstructured":"Teachey DT, Lacey SF, Shaw PA, et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov. 2016;6:664\u201379. https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0040.","journal-title":"Cancer Discov"},{"key":"167_CR19","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0698.","journal-title":"Cancer Discov"},{"key":"167_CR20","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","volume":"29","author":"N Gazeau","year":"2023","unstructured":"Gazeau N, Liang EC, Wu QV, et al. Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplant Cell Ther. 2023;29:430\u20137. https:\/\/doi.org\/10.1016\/j.jtct.2023.04.001.","journal-title":"Transplant Cell Ther"},{"key":"167_CR21","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","volume":"29","author":"JH Park","year":"2023","unstructured":"Park JH, Nath K, Devlin SM, et al. CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results. Nat Med. 2023;29:1710\u20137. https:\/\/doi.org\/10.1038\/s41591-023-02404-6.","journal-title":"Nat Med"},{"key":"167_CR22","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, et al. Clinical and biologic correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discov. 2018;8:958\u201371. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1319.","journal-title":"Cancer Discov"},{"key":"167_CR23","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1182\/blood.2023023419","volume":"144","author":"J Kim","year":"2024","unstructured":"Kim J, Cho J, Lee MH, Yoon SE, Kim WS, Kim SJ. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis. Blood. 2024;144:629\u201338. https:\/\/doi.org\/10.1182\/blood.2023023419.","journal-title":"Blood"},{"key":"167_CR24","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","volume":"5","author":"M Pennisi","year":"2021","unstructured":"Pennisi M, Jain T, Santomasso BD, et al. Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Adv. 2021;5:3397\u2013406. https:\/\/doi.org\/10.1182\/bloodadvances.2020003885.","journal-title":"Blood Adv"},{"key":"167_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-026-15877-8","volume":"26","author":"L Ye","year":"2026","unstructured":"Ye L, Liao L, Wang L, et al. Prediction models for CAR-T cell therapy-related adverse events in hematologic malignancies: a systematic review and meta-analysis. BMC Cancer. 2026;26:624. https:\/\/doi.org\/10.1186\/s12885-026-15877-8.","journal-title":"BMC Cancer"},{"key":"167_CR26","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1111\/bjh.70488","volume":"208","author":"Y Arai","year":"2026","unstructured":"Arai Y, Jo T, Sato T, et al. Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma. Br J Haematol. 2026;208:2124\u201333. https:\/\/doi.org\/10.1111\/bjh.70488.","journal-title":"Br J Haematol"},{"key":"167_CR27","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-025-01338-1","volume":"15","author":"M Winkelmann","year":"2025","unstructured":"Winkelmann M, Raj SS, Jain MD, et al. Optimization and validation of the international metabolic prognostic index for CD19 CAR-T in large B-cell lymphoma. Blood Cancer J. 2025;15:144. https:\/\/doi.org\/10.1038\/s41408-025-01338-1.","journal-title":"Blood Cancer J"},{"key":"167_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.bict.2025.100006","volume":"1","author":"M Tienstra","year":"2025","unstructured":"Tienstra M, Storck TN, van der Gali\u00ebn HT, et al. Early ICANS recognition with a novel electroencephalogram-based deltawave detection system in patients receiving CAR T-cell therapy. Blood Immunol Cell Ther. 2025;1:100006. https:\/\/doi.org\/10.1016\/j.bict.2025.100006.","journal-title":"Blood Immunol Cell Ther"},{"key":"167_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.clml.2024.12.011","volume":"25","author":"A Suresh","year":"2025","unstructured":"Suresh A, Wishart HA, Arslan MN, et al. Novel neurocognitive testing tool for early neurotoxicity detection following anti-CD19 and anti-BCMA chimeric antigen receptor (CAR) T-cell therapy: a pilot study. Clin Lymphoma Myeloma Leuk. 2025;25:365\u201378. https:\/\/doi.org\/10.1016\/j.clml.2024.12.011.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"167_CR30","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/blood.2023022432","volume":"143","author":"JL Crombie","year":"2024","unstructured":"Crombie JL, Graff T, Falchi L, et al. Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy. Blood. 2024;143:1565\u201375. https:\/\/doi.org\/10.1182\/blood.2023022432.","journal-title":"Blood"},{"issue":"2 Suppl","key":"167_CR31","doi-asserted-by":"publisher","first-page":"S523","DOI":"10.1016\/j.jtct.2025.12.783","volume":"32","author":"A Piela","year":"2026","unstructured":"Piela A, Ryan M, Bauer S, et al. Development and implementation of a CRS and ICANS monitoring process for outpatient cellular therapy. Transplant Cell Ther. 2026;32(2 Suppl):S523.","journal-title":"Transplant Cell Ther"},{"key":"167_CR32","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Management of Immunotherapy-Related Toxicities. Version 2.2026. National Comprehensive Cancer Network; 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf. Accessed 3 Jul 2026."},{"key":"167_CR33","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978\u201392. https:\/\/doi.org\/10.1200\/JCO.21.01992.","journal-title":"J Clin Oncol"},{"key":"167_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/bjh.17673","volume":"195","author":"MS Topp","year":"2021","unstructured":"Topp MS, van Meerten T, Houot R, et al. Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;195:388\u201398. https:\/\/doi.org\/10.1111\/bjh.17673.","journal-title":"Br J Haematol"},{"key":"167_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/bjh.17527","volume":"194","author":"OO Oluwole","year":"2021","unstructured":"Oluwole OO, Bouabdallah K, Munoz J, et al. Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma. Br J Haematol. 2021;194:690\u2013700. https:\/\/doi.org\/10.1111\/bjh.17527.","journal-title":"Br J Haematol"},{"key":"167_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41409-023-02169-z","volume":"59","author":"OO Oluwole","year":"2024","unstructured":"Oluwole OO, Forcade E, Mu\u00f1oz J, et al. Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids. Bone Marrow Transplant. 2024;59:366\u201372. https:\/\/doi.org\/10.1038\/s41409-023-02169-z.","journal-title":"Bone Marrow Transplant"},{"key":"167_CR37","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1182\/blood.2020008865","volume":"137","author":"P Strati","year":"2021","unstructured":"Strati P, Ahmed S, Furqan F, et al. Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma. Blood. 2021;137:3272\u20136. https:\/\/doi.org\/10.1182\/blood.2020008865.","journal-title":"Blood"},{"key":"167_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70248","volume":"9","author":"E Luttwak","year":"2025","unstructured":"Luttwak E, Nemirovsky D, Devlin SM, et al. Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma. HemaSphere. 2025;9:e70248. https:\/\/doi.org\/10.1002\/hem3.70248.","journal-title":"HemaSphere"},{"key":"167_CR39","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.jtct.2024.08.018","volume":"30","author":"FL Locke","year":"2024","unstructured":"Locke FL, Neelapu SS, Bartlett NL, et al. Tocilizumab prophylaxis following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Transplant Cell Ther. 2024;30:1065\u201379. https:\/\/doi.org\/10.1016\/j.jtct.2024.08.018.","journal-title":"Transplant Cell Ther"},{"key":"167_CR40","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","volume":"7","author":"P Strati","year":"2023","unstructured":"Strati P, Jallouk A, Deng Q, et al. A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma. Blood Adv. 2023;7:6785\u20139. https:\/\/doi.org\/10.1182\/bloodadvances.2023010653.","journal-title":"Blood Adv"},{"key":"167_CR41","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1182\/bloodadvances.2024015161","volume":"9","author":"MJ Frigault","year":"2025","unstructured":"Frigault MJ, Yao N, Berger TR, et al. Single-cell dynamics of breakthrough toxicities after anakinra prophylaxis for axicabtagene ciloleucel in lymphoma. Blood Adv. 2025;9:2122\u201335. https:\/\/doi.org\/10.1182\/bloodadvances.2024015161.","journal-title":"Blood Adv"},{"key":"167_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2026.06.008","author":"N Easton","year":"2026","unstructured":"Easton N, Andreoli M, van Besien H, et al. Real-world assessment of prophylactic anakinra on neurotoxicity and cytokine release syndrome after CD19 CAR T-cell therapy in relapsed\/refractory B-cell lymphoma: an inverse probability of treatment weighting analysis. Transplant Cell Ther. 2026. https:\/\/doi.org\/10.1016\/j.jtct.2026.06.008.","journal-title":"Transplant Cell Ther"},{"key":"167_CR43","doi-asserted-by":"publisher","first-page":"2430","DOI":"10.1182\/blood.2022017414","volume":"141","author":"MD Jain","year":"2023","unstructured":"Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430\u201342. https:\/\/doi.org\/10.1182\/blood.2022017414.","journal-title":"Blood"},{"key":"167_CR44","doi-asserted-by":"publisher","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006.","volume":"29","author":"A Bajwa","year":"2023","unstructured":"Hines MR, Knight TE, McNerney KO, et al. Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther. 2023;29:438.e1\u2013438.e16. https:\/\/doi.org\/10.1016\/j.jtct.2023.03.006.","journal-title":"Transplant Cell Ther"},{"key":"167_CR45","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/bloodadvances.2024013688.","volume":"9","author":"MR Hines","year":"2025","unstructured":"Bajwa A, Zhao Q, Geer M, et al. Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis. Blood Adv. 2025;9:170\u20135. https:\/\/doi.org\/10.1182\/bloodadvances.2024013688.","journal-title":"Blood Adv"},{"key":"167_CR46","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","volume":"109","author":"JJ Scala","year":"2024","unstructured":"Scala JJ, Eckrich MJ, Lipak K, et al. Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series. Haematologica. 2024;109:3439\u201345. https:\/\/doi.org\/10.3324\/haematol.2023.284784.","journal-title":"Haematologica"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00167-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-026-00167-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-026-00167-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T12:10:06Z","timestamp":1788955806000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-026-00167-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["167"],"URL":"https:\/\/doi.org\/10.1007\/s44313-026-00167-w","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"3 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"51"}}